Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Grifols SAGRFS9.460.790.6814.712.71%0.23%56.51$8.69$26.778,384$8.71

Detail of Grifols SA

 
CEO
Mr. Jose Ignacio Abia Buenache
Employees
23000
Industry
Drug Manufacturers—General
Sector
Healthcare
Market cap
$6B

Company details

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$7.14B
Cost of goods (CoG)
-$4.36B
Gross profit (GP)
$2.78B
Operating expense (OE)
-$1.75B
Research and development (R&D)
-$394.68M
General and administrative (G&A)
-$1.36B
Operating income (OI)
$924.72M
Other income expense (OIE)
-$172.36M
Pretax income (PI)
$397.47M
Tax (TAX)
-$116.73M
Net income (NI)
$280.74M
Grifols SA
GRFS • XNGS • US
$8.71
+0.56 (6.87%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$0.658025
Payout ratio
0.00%
EPS
$0.92
Margin profit
2.30%
52 week low
$5.47
52 week high
$9.76
50-day simple moving average
$0.00
200-day simple moving average
$8.69
Percent held by insiders
0.00%
Percent held by institutions
56.20%
Dividend yield
9.25%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
GRFS +7.00%
eps change
GRFS -13.34%